Merck: trial in endometrial cancer fails
The trial evaluated the efficacy of the combination of the monoclonal antibody and chemotherapy in newly-diagnosed, high-risk endometrial cancer patients who had undergone surgery.
The study did not, however, meet its primary endpoint, which was based on progression-free survival.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction